Concepedia

Ann‐Charlotte Egnell

AE

8

Publications

731

Citations

8

H-Index

2001

Active since

Affiliations

AstraZeneca (Sweden)(Current)

Karolinska Institutet

Moderna Therapeutics (United States)

Ann‐Charlotte Egnell is an author at AstraZeneca (Sweden) specializing in drug discovery, medicinal chemistry, and natural sciences.

Top concepts

Publications per year

2001–2019

8

Publications

8

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Li‐Ming Gan, Maria Lagerström‐Fermér, Leif Carlsson et al. · Nature Communications · 2019 · 209 citations · Full text

Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine

Leif Carlsson, Jonathan Clarke, Christopher Yen et al. · Molecular Therapy — Methods & Clinical Development · 2018 · 167 citations · Full text

Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.

Tashinga E. Bapiro, Ann‐Charlotte Egnell, Julia A. Hasler et al. · PubMed · 2001 · 118 citations

, , +18

In Vivo CYP3A4 Heteroactivation Is a Possible Mechanism for the Drug Interaction between Felbamate and Carbamazepine

Ann‐Charlotte Egnell, Brian Houston, Scott Boyer · Journal of Pharmacology and Experimental Therapeutics · 2003 · 74 citations

Changes in Matrix Proteoglycans Induced by Insulin and Fatty Acids in Hepatic Cells May Contribute to Dyslipidemia of Insulin Resistance

Urban Olsson, Ann‐Charlotte Egnell, M Lee et al. · Diabetes · 2001 · 53 citations

Rows per page

1–5 of 8